Pleiotrophin signals through ALK receptor to enhance growth of neurons in the presence of inhibitory CSPGs

Chondroitin sulfate proteoglycans (CSPGs), one of the major extracellular matrix components of the glial scar that surrounds central nervous system (CNS) injuries, are known to inhibit the regeneration of neurons. This study investigated whether pleiotrophin (PTN), a growth factor upregulated during early CNS development, can overcome the inhibition mediated by CSPGs and promote the neurite outgrowth of neurons in vitro . The data showed that a CSPG matrix inhibited the outgrowth of neurites in primary cortical neuron cultures compared to a control matrix. PTN elicited a dose dependent increase in the neurite outgrowth even in the presence of the growth inhibitory CSPG matrix, with optimal growth at 15 ng mL -1 of PTN (114.8% of neuronal outgrowth relative to laminin control). The growth promoting effect of PTN was blocked by inhibition of the receptor anaplastic lymphoma kinase (ALK) by alectinib in a dose dependent manner. Neurite outgrowth in the presence of this CSPG matrix was induced by activation of the protein kinase B (AKT) pathway, a key downstream mediator of ALK activation. This study identified PTN as a dose-dependent regulator of neurite outgrowth in primary cortical neurons cultured in the presence of a CSPG matrix, and identified ALK activation as a key driver of PTN-induced growth. Summary statement Function in the central nervous system (CNS) is attributed to the complex interactions of neurons and glia. These cells are anchored in extracellular matrix (ECM) which constitutes about 10% - 20% of brain volume. Cells in the brain produce different components of the ECM in brain including chondroitin sulfate proteoglycans (CSPGs). After a nervous system injury, glial cells produce excess CSPGs that restrict the regeneration of neurons, thus limiting functional recovery. This study examines the role of the endogenous growth factor pleiotrophin (PTN) in driving the growth of neurons even in the presence of inhibitory CSPGs, and anaplastic lymphoma kinase (ALK) receptor as a key mediator by which PTN potentiates growth.